4 enrolling by invitation. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Enrolling by invitation 4 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML Dexamethasone plus Venetoclax-based Low-Intensity Therapy - AML - Acute Myeloid Leukemia | Phase 1 | Enrolling by invitation | University of Vermont | 20 | 2025-09-01 | 2025-10-06 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-11-04 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
Leukemia, Myeloid, Acute (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms, Castration-Resistant (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms by Histologic Type (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Leukemia, Myeloid (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Chronic Disease (2) · Disease Attributes (2) · Leukemia, B-Cell (2)
Cyclophosphamide (1) · Dexamethasone (1) · JNJ-64264681 (1) · JNJ-64619178 (1) · fludarabine (1) · ibrutinib (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Research & Development, LLC (1) · University of Maryland, Baltimore (1) · University of Vermont (1)
United States (2) · Australia (1) · Belgium (1) · China (1) · Denmark (1) · France (1) · Georgia (1) · Greece (1) · Israel (1) · Japan (1) · Moldova (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1)